Cytovale
At Cytovale, we’re focused on more rapid and insightful ways to diagnose fast-moving and immune-mediated diseases.
At Cytovale, we’re focused on more rapid and insightful ways to diagnose fast-moving and immune-mediated diseases.
Cytovale:
Cytovale, a medical diagnostics company founded in 2013, is focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Their FDA cleared IntelliSep test pioneers a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis in under 10 minutes.
Their first market application will be for sepsis, a condition responsible for the most hospital deaths in the U.S. Cytovale aims to provide critical insight for the early identification of patients at risk of sepsis, making early detection essential.
The company recently secured an $84.00M Series C investment led by Norwest Venture Partners, Sands Capital Ventures, Alumni Ventures Blockchain Fund, and Global Health Investment Corporation on 15 November 2023.
Cytovale’s innovative approach to diagnosing sepsis, a critical and time-sensitive healthcare issue, positions it well for significant impact in the medical diagnostics industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | $84.00M | 4 |
|
15 Nov 2023 |
| Debt Financing | $16.44M | 4 |
|
04 Jan 2021 |
| Series B | $15.00M | 4 |
|
30 Oct 2019 |
| Series B | Unknown | 1 |
|
08 Nov 2018 |
| Series B | $7.25M | 3 |
|
22 Dec 2017 |
No recent news or press coverage available for Cytovale.
We care about your data, and we'd love to use cookies make your experience better.
